U.S. markets open in 1 hour 33 minutes
  • S&P Futures

    3,601.75
    +25.75 (+0.72%)
     
  • Dow Futures

    29,844.00
    +298.00 (+1.01%)
     
  • Nasdaq Futures

    11,936.50
    +31.25 (+0.26%)
     
  • Russell 2000 Futures

    1,840.80
    +23.70 (+1.30%)
     
  • Crude Oil

    43.65
    +0.59 (+1.37%)
     
  • Gold

    1,808.30
    -29.50 (-1.61%)
     
  • Silver

    23.18
    -0.45 (-1.90%)
     
  • EUR/USD

    1.1868
    +0.0022 (+0.19%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.04
    -1.66 (-7.00%)
     
  • GBP/USD

    1.3323
    +0.0001 (+0.00%)
     
  • USD/JPY

    104.5160
    +0.0280 (+0.03%)
     
  • BTC-USD

    19,073.77
    +621.80 (+3.37%)
     
  • CMC Crypto 200

    375.98
    +14.55 (+4.03%)
     
  • FTSE 100

    6,400.68
    +66.84 (+1.06%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum

T2 Biosystems, Inc.
·1 min read

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.

Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406